The estimated Net Worth of Sasha King is at least $8.64 Milione dollars as of 9 June 2021. Ms. King owns over 12,435 units of Caredx Inc stock worth over $1,145,166 and over the last 7 years she sold CDNA stock worth over $6,203,299. In addition, she makes $1,292,340 as Chief Marketing Officer at Caredx Inc.
Sign up
Ms. King CDNA stock SEC Form 4 insiders trading
Sasha has made over 18 trades of the Caredx Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 12,435 units of CDNA stock worth $1,119,274 on 9 June 2021.
The largest trade she's ever made was selling 40,775 units of Caredx Inc stock on 8 October 2020 worth over $2,064,031. On average, Sasha trades about 4,872 units every 25 days since 2017. As of 9 June 2021 she still owns at least 40,139 units of Caredx Inc stock.
You can see the complete history of Ms. King stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sasha King biography
Sasha King M.B.A. serves as Chief Marketing Officer of the Company. Prior to that, she served as our Chief Commercial Officer from October 2017 to June 2019. Ms. King brings over 10 years of diagnostics and genetic testing experience. Prior to becoming our Chief Commercial Officer, she served as our Ad Interim Chief Commercial Officer from June to October 2017 and as our Head of Marketing from March to June 2017. From August 2015 to March 2017, she worked in companion diagnostics marketing at Genentech, and was a sales leader at Ariosa Diagnostics from July 2013 to August 2015. While at Genentech, she worked on the launch of the first FDA approved cell free DNA test in oncology, the PD-Ll test launch, and the Foundation Medicine partnership. Ms. King was an early member of the commercial team at Ariosa, a leader in the field of noninvasive prenatal testing (“NIPT”), which is now part of the Roche Group. She led the launch of their test into Asia Pacific and Canada. From August 2008 to July 2011, Ms. King worked at Fletcher Spaght, a life science consulting and venture capital fund. She received a bachelor of science in bioengineering from Massachusetts Institute of Technology in 2008 and an M.B.A. from Stanford Graduate School of Business in 2013.
What is the salary of Sasha King?
As the Chief Marketing Officer of Caredx Inc, the total compensation of Sasha King at Caredx Inc is $1,292,340. There are 4 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
How old is Sasha King?
Sasha King is 34, she's been the Chief Marketing Officer of Caredx Inc since 2019. There are 16 older and no younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
What's Sasha King's mailing address?
Sasha's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Insiders trading at Caredx Inc
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon e Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
What does Caredx Inc do?
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
What does Caredx Inc's logo look like?
Complete history of Ms. King stock trades at Caredx Inc
Caredx Inc executives and stock owners
Caredx Inc executives and other stock owners filed with the SEC include:
-
Peter Maag,
Executive Chairman of the Board of Directors -
Michael Bell,
Chief Financial Officer -
Reginald Seeto,
President, Chief Executive Officer, Director -
Dr. Peter Maag Ph.D.,
Exec. Director -
Sasha King,
Chief Marketing Officer -
Alexander L. Johnson,
Pres of Patient and Testing Services -
Sasha King M.B.A.,
Chief Marketing Officer & Franchise Head of Kidney Transplant -
Marcel Konrad,
Sr. VP of Fin. and Accounting & Corp. Controller -
Michael Goldberg,
Lead Independent Director -
Grace Colon,
Independent Director -
Christine Cournoyer,
Independent Director -
Ralph Snyderman,
Independent Director -
George Bickerstaff,
Independent Director -
Frederick Cohen,
Independent Director -
William Hagstrom,
Independent Director -
David Clair,
IR Contact Officer -
Marica Grskovic Ph.D.,
Chief Operating Officer -
Abhishek Jain,
CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer -
Dr. Mickey Y. Kim M.D.,
Sr. VP of Corp. Devel. & Strategy -
Abraham Ronai Esq.,
Gen. Counsel, Chief Admin. & Legal Officer and Sec. -
Ian Cooney,
VP of Investor Relations -
Amitabh Shukla,
Sr. VP of Technology -
Paul Ciccolella,
Sr. VP of Global Operations -
Ankur Dhingra,
Chief Financial Officer -
Charles Constanti,
Chief Financial Officer -
Douglas S Miller,
Director -
Todd Whitson,
Chief Commercial Officer -
Brook H Byers,
Director -
John Joseph Sninsky,
Chief Scientific Officer -
James P Yee,
Chief Medical Officer -
Neil Gagnon,
10% owner -
Mitchell J Nelles,
Chief Operating Officer -
Anders Karlsson,
See Remarks -
Richard Bryan Riggsbee,
Director -
Amy Abernethy,
Director -
Fred E Cohen,
-
Ken Ludlum,
Chief Financial officer -
Matthew J. Meyer,
Chief Business Officer -
Joshua De Fonzo,
Chief Commercial Officer -
Perkins Caufield & Byers X ...,
-
Group Holdings (Sbs) Adviso...,
-
Abraham Ronai,
See Remarks -
Abhishek Jain,
Chief Financial Officer -
Ankur Dhingra,
Chief Financial Officer -
Hannah Valantine,
-
Arthur A Torres,
-
Alexander L Johnson,
See Remarks -
Jeffrey Adam Novack,
Secretary and General Counsel